<qa>  What is the method to evaluate the factors affecting PK and PD variability?V. Characterize differences in chemokines CCL2 and CCL5 and other cytokines in blood of patients prior to and after administration of glembatumumab vedotin and nivolumab as a method to evaluate the factors affecting PK and PD variability and mechanisms of drug-drug interactions. 